X

Trial Profile

A clinical trial of ABO 101 for primary hyperoxaluria type 1 (PH1)

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 25 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABO 101 Arbor Biotechnologies (Primary)
Indications Hyperoxaluria
Focus Adverse reactions
Acronyms RedePHine

Most Recent Events

19 Dec 2024 According to an Arbor Biotechnologies media , RedePHine phase 1/2 clinical trial initiation expected in first half of 2025.
19 Dec 2024 According to an Arbor Biotechnologies media release, the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ABO-101, a novel gene editing therapeutic designed to address primary hyperoxaluria type 1 (PH1).
25 Oct 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com